FilingReader Intelligence

Fosun Pharma subsidiary enters licensing agreement with FBD

June 30, 2025 at 05:10 PM UTCBy FilingReader AI

Shanghai Fosun Pharmaceutical Group announced that its holding subsidiary, Henlius, has entered into a licensing agreement with FBD for the development, production, and commercialization of FBD's investigational drug, HCB101 (a SIRPa-Fc fusion protein), and any drugs containing this molecule as their active ingredient, within specified regions and therapeutic areas focused on human disease treatment. Under the agreement, Henlius will pay FBD up to USD 59 million in upfront and milestone payments, plus up to USD 14.3 million in commercial milestone payments based on annual net sales in the licensed territory. Additionally, Henlius will pay royalties on net sales of licensed products within the designated region. Henlius will have preferential negotiation rights for development and commercialization in Japan. The collaboration aims to strengthen Fosun Pharma's pipeline in the oncology field.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SSE:600196Shanghai Stock Exchange
PharmaceuticalsShanghai Blue Chip

News Alerts

Get instant email alerts when Shanghai Fosun Pharmaceutical Group publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →